Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 2—February 2016

Feasibility of Xpert Ebola Assay in Médecins Sans Frontières Ebola Program, Guinea

Rafael Van den BerghComments to Author , Pascale Chaillet, Mamadou Saliou Sow, Mathieu Amand, Charlotte van Vyve, Sylvie Jonckheere, Rosa Crestani, Armand Sprecher, Michel Van Herp, Arlene Chua, Erwan Piriou, Lamine Koivogui, and Annick Antierens
Author affiliations: Médecins Sans Frontières, Brussels, Brussels, Belgium (R. Van den Bergh, P. Chaillet, R. Crestani, A. Sprecher, M. Van Herp, A. Antierens); Hôpital National Donka, Conakry, Guinea (M.S. Sow); Comité de Recherche Ebola de Guinée, Conakry (M.S. Sow); Médecins Sans Frontières, Conakry (M. Amand, C. van Vyve, S. Jonckheere); Médecins Sans Frontières, Geneva, Switzerland (A. Chua); Institute of Infectious Diseases and Epidemiology, Singapore (A. Chua); Médecins Sans Frontières, Amsterdam, Amsterdam, the Netherlands (E. Piriou); Institut National de Santé Publique, Conakry (L. Koivogui)

Main Article

Table 1

Characteristics of 148 patients and 218 blood samples collected for analysis by Xpert Ebola Assay at Médecins Sans Frontières Donka Ebola Treatment Center, Conakry, Guinea, May–June 2015

No. (%)
Patient sex
F 59 (40)
89 (60)
Patient age, y
2–4 15 (10)
5–18 19 (13)
19–45 84 (57)
46–64 16 (11)
>65 11 (7)
Not recorded 3 (2)
Sample type
Diagnosis 1* 147 (67)
Diagnosis 2 (confirmation) 52 (24)
After transfusion 12 (6)
Convalescent phase 7 (3)

*One patient (2-year-old boy) did not have an initial diagnostic sample obtained for the study.

Main Article

Page created: January 13, 2016
Page updated: January 13, 2016
Page reviewed: January 13, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.